| June 9, 2008
DOT warns against anti-smoking drug
Chantix
CLEVELAND, June 9 — On June 5, the U.S. Department
of Transportation warned the Federal Railroad Administration
about the possible dangers of rail workers in safety sensitive
positions using an anti-smoking drug known as Chantix.
The Federal Aviation Administration has banned the use of
Chantix by pilots and air traffic controllers, and the Federal
Motor Carrier Safety Administration has urged medical examiners
not to certify a commercial driver who uses this drug.
In a memo from the DOT’s Office of Drug and Alcohol
Policy and Compliance to the FRA’s Office of Safety,
the DOT warned that the drug may be linked to more than 100
accidents, as well as seizures, dizziness, heart irregularity,
heart attacks, loss of consciousness, vision problems and
diabetes.
A complete copy of the study is available at: http://www.ismp.orgldocs/vareniclineStudy.asp
Accordingly, the DOT has asked BLET to disseminate the following
statement to its membership:
“The U.S. Department of Transportation reminds all
transportation industries of the potential threat to public
safety caused by the use of the anti-smoking drug Chantix.
A recent independent study spoke of possible links to seizures,
dizziness, heart irregularity, loss of consciousness, vision
problems, diabetes, and more than 100 accidents. As a result,
we strongly urge all transportation industry employers to
include in their employee training materials appropriate
information to address this issue. We also encourage employers
to reiterate with their employees the need to report use
of such medications when required by applicable DOT regulations
or by company policies.”
BLET members are urged to be aware of the side effects of
this medication and should make sure their doctors are aware
of the safety-critical nature of their work if prescribed
Chantix.
The BLET National Division is asking its General Chairmen
and State Legislative Board Chairmen to make the following
memo available to their membership:
http://www.ble-t.org/pr/pdf/ChantixFRAMemo.pdf
|